Cellective raises $5M bridge for cancer diagnostics
Cellective Dx announced that it brought in a $5 million bridge to a $25 million second round of funding. The Mountain View, Calif.-based company will use the money to continue development of cancer diagnostic tools that analyze tumor cells in blood. The method is supposed to help doctors determine the best course of treatment.
The funding is expected to last through the end of 2010. That’s enough to span two more commercialized tests of the products, VentureWire reports. The bridge was provided by previous investors Mohr Davidow Ventures and Northgate Capital. The company, formerly named CellPoint Diagnostics, has brought in $19 million in capital total, having closed an $11.2 million first round last September.
Next Story: DigitalBridge lands $16.5M for rural wireless growth
Previous Story: The cloud gets better with Microsoft Office and Google Labs
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.